Brooklyn Immuno Therapeutics

Brooklyn ImmunoTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer and immunologic diseases. The company's primary focus is on IRX-2, a novel human cell-derived hd IL-2 based therapy designed to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. IRX-2 has shown promising results in Phase 2a clinical trials for head and neck cancer, demonstrating an increase in tumor-infiltrating lymphocytes and an associated survival benefit. Brooklyn ImmunoTherapeutics operates in the biopharmaceutical market, targeting healthcare providers and researchers specializing in oncology and immunotherapy. The company generates revenue through partnerships, grants, and potential future sales of its therapeutic products.

Keywords: biopharmaceutical, cancer therapy, immunotherapy, hd IL-2, IRX-2, clinical trials, tumor microenvironment, oncology, immune response, head and neck cancer.